

# Invitation to presentation of Xbrane Biopharma's interim report January – June 2025 on August 26, 2025

**Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Tuesday, August 26th, 2025, at 09.00 a.m. CET. Xbrane will publish the company's interim report January – June 2025, on Tuesday, August 26, 2025, at 8.00 a.m. CET.**

Martin Åmark, CEO, and Jane Benyamin, CFO/IR, will present the interim report January – June 2025, followed by a Q&A session. The presentation will be in English. To attend, please follow the link below:

**If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions.**

[Q2 Report 2025](#)

**If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.**

[Call Access](#)

## Contacts

Martin Åmark, CEO  
E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Jane Benyamin, CFO/IR  
E: [jane.benyamin@xbrane.com](mailto:jane.benyamin@xbrane.com)

## About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit [www.xbrane.com](http://www.xbrane.com)

Press Release  
21 August 2025 18:10:00 CEST



---

## Attachments

---

[Invitation to presentation of Xbrane Biopharma's interim report January – June 2025 on August 26, 2025](#)